鼻内皮质类固醇制剂治疗慢性鼻-鼻窦炎安全性与有效性的学术综述
A Scholarly Review of the Safety and Efficacy of Intranasal Corticosteroids Preparations in the Treatment of Chronic Rhinosinusitis.
作者信息
Macias-Valle Luis, Psaltis Alkis J
机构信息
Department of Otolaryngology Head and Neck Surgery, Hospital Español de México, 103472Universidad La Salle. México City, México.
Department of Otolaryngology Head and Neck Surgery, 1066University of Adelaide, Adelaide, Australia and Central Adelaide Local Health Network, South Australia.
出版信息
Ear Nose Throat J. 2021 Jun;100(5):295-301. doi: 10.1177/0145561320967727. Epub 2020 Oct 21.
OBJECTIVE
The purpose of this scholarly review is to present an update of the efficacy, safety, and distribution of intranasal corticosteroids (INCS) in the context of treatment for chronic rhinosinusitis (CRS).
MATERIALS AND METHODS
A literature review from 1999 to 2020 of MEDLINE, PubMed, and EMBASE databases was performed, using a comprehensive search strategy. Studies reporting on efficacy, safety, and distribution of all INCS formulations, both Food and Drug Administration (FDA) and non-FDA approved, were reviewed.
RESULTS AND CONCLUSIONS
High-level evidence publications and position papers support the role of INCS in medical treatment for CRS. Significant improvement in disease-specific and general quality of life measures is observed with all formulations of INCS. Overall, the use of both FDA and published non-FDA INCS appears to be safe. Several novel distribution devices might improve penetration to specific areas within the sinuses.
目的
本学术综述的目的是在慢性鼻-鼻窦炎（CRS）治疗背景下，对鼻内用糖皮质激素（INCS）的疗效、安全性及分布情况进行更新。
材料与方法
采用全面检索策略，对1999年至2020年MEDLINE、PubMed和EMBASE数据库进行文献综述。对所有已报道的INCS制剂（包括美国食品药品监督管理局（FDA）批准的和未批准的）的疗效、安全性及分布情况的研究进行了综述。
结果与结论
高水平证据的出版物和立场文件支持INCS在CRS药物治疗中的作用。所有INCS制剂均能使疾病特异性和总体生活质量指标得到显著改善。总体而言，FDA批准的和已发表的非FDA批准的INCS的使用似乎都是安全的。几种新型给药装置可能会提高鼻窦内特定区域的药物渗透率。
Zotero 插件